Posted by Michael Wonder on 16 Feb 2022
Poxel announces FDA fast track status for PXL065 in X linked adrenoleukodystrophy
16 February 2022 - The initiation of the Phase IIa proof of concept clinical study for PXL065 in adrenoleukodystrophy is now expected in mid-year, with results expected in early 2023.
Poxel announces that the U.S. FDA has granted fast track status to PXL065 for the treatment of patients with adrenomyeloneuropathy, the most common form of X linked adrenoleukodystrophy.
